Skip to content

Sarcopenia in Children

Sarcopenia; a New Issue in Juvenile Idiopathic Arthritis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05291416
Enrollment
60
Registered
2022-03-22
Start date
2022-04-01
Completion date
2022-12-31
Last updated
2022-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile Idiopathic Arthritis, Sarcopenia

Brief summary

Juvenile idiopathic arthritis (AJI), is a frequent inflammatory disease in children, characterized by pain, arthritis, and deformities. Chronic inflammation leads to physical inactivity and can be associated with muscle weakness around affected joints, low bone strength, and mass(3). To our knowledge, no study has focused on the prevalence of sarcopenia in JIA and the data on the muscle disorder are lacking. The purpose of the present study is to detect sarcopenia and identify associated factors in children with JIA

Interventions

DIAGNOSTIC_TESTdensitometry/ handgrip dynamometer

all patients will undergo the Dual-energy X-ray absorptiometry (DXA) and the muscle strength assessment using the handgrip dynamometer

Sponsors

University Tunis El Manar
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
4 Years to 16 Years
Healthy volunteers
Yes

Inclusion criteria

* children with juvenile idiopathic arthritis fulfilling the ILAR criteria

Exclusion criteria

* We excluded patients who have a prosthesis, nutritional problems, inflammatory bowel disease, coeliac disease, temporomandibular involvement, or another chronic disease.

Design outcomes

Primary

MeasureTime frameDescription
skeletal muscle mass4 monthsDual-energy X-ray absorptiometry (DXA) measures the appendicular lean mass ( the sum of the lean mass of the arms and legs) and adjusted to the body mass index

Secondary

MeasureTime frameDescription
muscle strenght5 monthsThree consecutive trials will be measured by the handgrip dynamometer between the dominant and non-dominant sides. the highest value will be used and adjusted to the body mass index

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026